Ligand Pharmaceuticals (LGND) Income towards Parent Company (2018 - 2025)
Ligand Pharmaceuticals' Income towards Parent Company history spans 15 years, with the latest figure at $44.8 million for Q4 2025.
- For Q4 2025, Income towards Parent Company rose 244.06% year-over-year to $44.8 million; the TTM value through Dec 2025 reached $124.5 million, up 500.32%, while the annual FY2025 figure was $124.5 million, 3186.63% up from the prior year.
- Income towards Parent Company for Q4 2025 was $44.8 million at Ligand Pharmaceuticals, down from $117.3 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $117.3 million in Q3 2025 and bottomed at -$42.5 million in Q1 2025.
- The 5-year median for Income towards Parent Company is -$3.8 million (2021), against an average of $3.2 million.
- The largest annual shift saw Income towards Parent Company plummeted 136.03% in 2022 before it soared 244.06% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$2.2 million in 2021, then tumbled by 32.75% to -$3.0 million in 2022, then skyrocketed by 43.58% to -$1.7 million in 2023, then tumbled by 1767.15% to -$31.1 million in 2024, then skyrocketed by 244.06% to $44.8 million in 2025.
- Per Business Quant, the three most recent readings for LGND's Income towards Parent Company are $44.8 million (Q4 2025), $117.3 million (Q3 2025), and $4.8 million (Q2 2025).